Ownership and insider activity for Opus Genetics, Inc. (IRD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
Price
| Price | $5.41 |
| Market Cap | $447M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-09 | Magrath George | M-Exempt | 392,157 | $451K |
| 2026-09-09 | Magrath George | F-InKind | 75,541 | $451K |
| 2026-09-09 | Magrath George | M-Exempt | 392,157 | $451K |
| 2026-09-08 | Gallagher Cam | M-Exempt | 784,314 | $902K |
| 2026-09-08 | Gallagher Cam | M-Exempt | 784,314 | $902K |
| 2026-09-03 | Gagnon Robert E. | S-Sale | 28,000 | $127K |
| 2026-07-23 | YERXA BENJAMIN R | S-Sale | 7,429 | $22K |
| 2026-07-23 | SCHACHLE JOSEPH K | S-Sale | 4,644 | $14K |
| 2026-07-23 | Magrath George | S-Sale | 9,475 | $28K |
| 2026-07-23 | Gagnon Robert E. | S-Sale | 7,783 | $23K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.5M | $16.4M | $24.5M | $42.6M | $50.5M | $30.3M | $45.1M |
| Short-term Investments | 0 | 0 | $219000 | $49000 | $15000 | $2000 | 0 |
| Receivables | $125000 | 0 | 0 | $4.8M | $2.3M | $5.8M | $3.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.8M | $17.7M | $26.1M | $49.0M | $53.9M | $36.6M | $50.0M |
| Property, Plant & Equipment | $22000 | $14000 | $10000 | $6000 | 0 | $252000 | $199000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1.8M | $17.7M | $26.1M | $49.0M | $53.9M | $36.9M | $50.2M |
| Accounts Payable | $342000 | $1.2M | $1.6M | $1.1M | $2.2M | $3.1M | $3.3M |
| Short-term Debt | $5.7M | 0 | $538000 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $9.3M | $3.2M | $3.9M | $2.8M | $4.0M | $11.3M | $7.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $9.3M | $31.1M | $3.9M | $2.8M | $4.0M | $30.1M | $34.9M |
| Retained Earnings | -$8.1M | -$32.7M | -$89.4M | -$71.5M | -$81.5M | -$139.0M | -$188.6M |
| Total Equity | -$7.6M | -$13.5M | $22.2M | $46.2M | $49.9M | $6.7M | $15.3M |
| Total Debt | $5.7M | 0 | $538000 | 0 | 0 | 0 | 0 |
| Net Debt | $4.1M | -$16.4M | -$24.2M | -$42.7M | -$50.5M | -$30.3M | -$45.1M |
| Working Capital | -$7.6M | $14.5M | $22.2M | $46.2M | $49.9M | $25.3M | $42.3M |
Financial Health
| Debt / Equity | -2.69 |
| Current Ratio | 12.19 |
Profitability
| Return on Equity | 1147.63% |
| Return on Invested Capital | -59.29% |
| Return on Assets | -115.75% |
| Gross Margin | 99.87% |
| Operating Margin | -513.47% |
| Net Margin | -1091.82% |
Related companies: ABOS · AGEN · ALEC · CGTX · HURA · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of IRD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks